Hunan Creator Information Technologies
300730
Shandong Rike Chemical
300214
Jiangsu LiXing General Steel Ball
300421
4
Jiangsu Boiln Plastics
301003
5
Ningbo Henghe Precision Industry
300539
US Stock MarketDetailed Quotes
KAPA Kairos Pharma
- 1.140
- -0.050-4.20%
Close Feb 25 16:00 ET
- 1.230
- +0.090+7.89%
Post 20:01 ET
15.62MMarket Cap-5.43P/E (TTM)
1.250High1.140Low133.96KVolume1.160Open1.190Pre Close160.20KTurnover8.64%Turnover RatioLossP/E (Static)13.70MShares4.00052wk High4.69P/B1.77MFloat Cap0.85152wk Low--Dividend TTM1.55MShs Float4.000Historical High--Div YieldTTM9.24%Amplitude0.851Historical Low1.195Avg Price1Lot Size
About Kairos Pharma Company
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.
Company Profile
SymbolKAPA
Company NameKairos Pharma
Listing DateSep 16, 2024
Founded2013
CEODr. John S. Yu,M.D.
MarketAMEX
Employees3
Fiscal Year Ends12-31
Address2355 Westwood Boulevard,Suite 139
CityLos Angeles
ProvinceCalifornia
CountryUnited States of America
Zip Code90064
Phone1-310-948-2356
Websitehttp://kairospharma.com
Company Executives
- Name
- Position
- Salary
- Dr. John S. Yu,M.D.
- Chairman of the Board and Chief Executive Officer
- --
- Neil Bhowmick
- Chief Scientific Officer
- --
- Doug Samuelson
- Chief Financial Officer
- --
- Ramachandran Murali, PhD
- Vice President of Research and Development
- --
- Dr. Rahul Singhvi, Sc.D.
- Director
- --
- Dr. Hansoo Michael Keyoung, M.D.,PhD
- Independent Director
- --
- Hyun W. Bae, M.D.
- Independent Director
- --
Trending Stocks
Discussing
Widespread uptick! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets.
Moomoo News Global
Feb 24 22:30
Chinese Stocks' Wild Rally Hits Pause? Wall Street Still Bets Big on Favorites